New drug plus standard chemotherapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial combines a new experimental drug (emavusertib) with standard chemotherapy (FOLFOX plus bevacizumab) for people with stage IV colorectal cancer who have not yet received chemotherapy. The goal is to see if the combination is safe and effective, potentially offering a new first-line treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer that has spread to other parts of the body (stage IV) and cannot be removed with surgery.
- You must not have had any prior chemotherapy for colorectal cancer, including standard treatments like FOLFOX or biological drugs like bevacizumab.
- Your tumor must not have a specific genetic feature called MSI-H or dMMR.
- You must be 18 years or older and able to take oral medications (pills).
- Your liver, kidney, and blood counts must be within normal ranges, and you must not have certain heart rhythm problems.
- You must be generally feeling well enough to perform daily activities (ECOG performance status 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial tests whether adding a drug called bevacizumab (which helps stop blood vessel growth to tumors) to a combination of two chemotherapy drugs (oxaliplatin and TAS-102) can help people with advanced colorectal cancer. It is for people who have not yet received treatment for their advanced cancer.
Hear when a new Metastatic Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.